Analysts predict that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will post sales of $22.14 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Lexicon Pharmaceuticals’ earnings. The highest sales estimate is $25.99 million and the lowest is $19.66 million. Lexicon Pharmaceuticals reported sales of $18.29 million in the same quarter last year, which would suggest a positive year over year growth rate of 21%. The firm is expected to issue its next earnings report on Tuesday, May 1st.
On average, analysts expect that Lexicon Pharmaceuticals will report full-year sales of $22.14 million for the current financial year, with estimates ranging from $67.55 million to $100.40 million. For the next year, analysts expect that the firm will report sales of $249.35 million per share, with estimates ranging from $204.97 million to $281.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.12. Lexicon Pharmaceuticals had a negative net margin of 142.86% and a negative return on equity of 143.31%. The company had revenue of $33.05 million during the quarter, compared to analyst estimates of $29.84 million. During the same period in the previous year, the business earned ($0.31) earnings per share. The firm’s quarterly revenue was up 43.7% compared to the same quarter last year.
LXRX has been the subject of several analyst reports. ValuEngine lowered shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. BidaskClub upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. Wedbush restated an “outperform” rating and set a $38.00 price target on shares of Lexicon Pharmaceuticals in a research report on Thursday, November 30th. Finally, JPMorgan Chase & Co. lowered shares of Lexicon Pharmaceuticals from a “neutral” rating to an “underweight” rating and cut their price target for the company from $15.00 to $10.00 in a research report on Wednesday, February 14th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $24.00.
Lexicon Pharmaceuticals stock opened at $8.59 on Monday. Lexicon Pharmaceuticals has a 1 year low of $7.80 and a 1 year high of $18.00. The company has a debt-to-equity ratio of 4.44, a current ratio of 2.59 and a quick ratio of 2.58.
Several large investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company raised its stake in shares of Lexicon Pharmaceuticals by 3.7% during the second quarter. The Manufacturers Life Insurance Company now owns 36,417 shares of the biopharmaceutical company’s stock valued at $599,000 after acquiring an additional 1,291 shares during the last quarter. Stifel Financial Corp raised its stake in shares of Lexicon Pharmaceuticals by 12.3% during the third quarter. Stifel Financial Corp now owns 80,419 shares of the biopharmaceutical company’s stock valued at $987,000 after acquiring an additional 8,833 shares during the last quarter. Jump Trading LLC bought a new position in shares of Lexicon Pharmaceuticals during the fourth quarter valued at about $104,000. Two Sigma Advisers LP bought a new position in shares of Lexicon Pharmaceuticals during the fourth quarter valued at about $104,000. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Lexicon Pharmaceuticals by 5.6% during the third quarter. Schwab Charles Investment Management Inc. now owns 204,129 shares of the biopharmaceutical company’s stock valued at $2,509,000 after acquiring an additional 10,811 shares during the last quarter.
COPYRIGHT VIOLATION WARNING: “Lexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Quarterly Sales of $22.14 Million” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/19/lexicon-pharmaceuticals-inc-lxrx-expected-to-announce-quarterly-sales-of-22-14-million.html.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.